Healthcare solutions provider Solventum (NYSE:SOLV) reported Q2 CY2026 results , with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ ...
Solventum has a few good businesses, but the market is treating it as a complicated company. Its main parts are MedSurg, Dental, HIS, and a smaller Water / All Other. The thesis says the stock looks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results